Stephen Long Net Worth

Stephen Long biography

Stephen J. Long serves as Secretary, Chief Legal Officer of the Company. Mr. Long served as Counsel at the law firm of Reed Smith LLP, from April 2013 to February 2015. He previously served at C.R. Bard, Inc., a medical device manufacturing company, from October 2000 to May 2012 in the roles of Vice President, General Counsel, as Vice President, and Secretary, and as Associate General Counsel. Mr. Long also served as Assistant General Counsel, Consumer Healthcare, at Warner-Lambert Company, and as Counsel for the company’s pharmaceutical division from February 1998 to September 2000. Mr. Long held positions earlier in his career at the law firm of Willkie Farr & Gallagher and Bankers Trust Company. Mr. Long received his B.S. from the School of Industrial and Labor Relations at Cornell University and his J.D. from Albany Law School of Union University.

How old is Stephen Long?

Stephen Long is 54, he's been the Secretary és Chief Legal Officer of Strongbridge Biopharma plc since 2015. There are 5 older and 3 younger executives at Strongbridge Biopharma plc. The oldest executive at Strongbridge Biopharma plc is David Gill, 65, who is the Independent Director.

What's Stephen Long's mailing address?

Stephen's mailing address filed with the SEC is 900 NORTHBROOK DRIVE, SUITE 200, TREVOSE, PA, 19053.

Insiders trading at Strongbridge Biopharma plc

Over the last 7 years, insiders at Strongbridge Biopharma plc have traded over $0 worth of Strongbridge Biopharma plc stock and bought 2,670,648 units worth $8,846,818 . The most active insiders traders include Associates, L.L.C.Caxton Co..., Garheng Kong és Jeffrey W Sherman. On average, Strongbridge Biopharma plc executives and independent directors trade stock every 89 days with the average trade being worth of $593,478. The most recent stock trade was executed by David N Gill on 24 September 2020, trading 8,000 units of SBBP stock currently worth $17,040.

What does Strongbridge Biopharma plc do?

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's rare endocrine franchise includes RECORLEV® (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing's syndrome, and veldoreotide extended release, a preclinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company's rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.

Strongbridge Biopharma plc executives and stock owners

Strongbridge Biopharma plc executives and other stock owners filed with the SEC include:

• Frederic Cohen,
  Chief Medical Officer
• Robert Lutz,
  Chief Financial Officer
• John Johnson,
  Chief Executive Officer
• Marten Steen,
  Independent Director
• Garheng Kong,
  Lead Independent Director
• Richard Kollender,
  Chief Operating Officer
• Hilde Steineger,
  Independent Director
• Jeffrey Sherman,
  Independent Director
• David Gill,
  Independent Director
• Stephen Long,
  Secretary, Chief Legal Officer
• Scott Wilhoit,
  Chief Commercial Officer
• A Brian Davis,
  Chief Financial Officer
• Matthew Pauls,
  President & CEO
• Fredric J. Cohen,
  Chief Medical Officer
• Associates, L.L.C.Caxton Co...,